
Session 4: Unleashing the Power of TB and Global Health Innovations Now and in the Future**30 October – 8:30-10:30****1. Purpose of the Session**

The Stop TB Partnership (STBP) has developed a **strong and growing portfolio of innovation-focused initiatives** designed to concretely, practically, and rapidly progress toward ending tuberculosis (TB). Through its flagship programs, the organization has built a unique ecosystem that **identifies, supports, introduces, and scales breakthrough solutions** across the TB response.

- **[TB REACH](#)** – supported primarily by *Global Affairs Canada* and the *United Kingdom (UK) Foreign, Commonwealth and Development Office (FCDO)*, **TB REACH** has become one of the go-to platforms in TB to evaluate innovations, in real-world settings to inform global and country level policies, to improve case detection and health service delivery.
- **[Digital Health Technology Hub](#)** - supported by *Unitaid* and the *United States (US) Centers for Disease Control and Prevention (CDC)* builds and expands the evidence, information, and experience of the appropriate use of digital health technologies. The initiative creates a space for our partners from country programs and implementing partners to learn about digital health technologies for the TB response and provide technical support to implement and scale-up these solutions.
- **[The introducing New Tools Project \(iNTP\)](#)** – supported by the *US Department of State*, iNTP focuses on catalyzing the programmatic introduction of next-generation TB diagnostics and digital tools. The project demonstrates the feasibility of these technologies and generates evidence to inform further scale-up and support experience sharing with other countries.
- **[Re-imagining TB Care \(RTC\) Initiative](#)** – supported primarily by the *Korea International Cooperation Agency (KOICA)*, *Ministry of Foreign Affairs of the Republic of Korea*, and *CDC*, RTC takes best practices from the private sector for the public sector, specifically for TB and global health, to change how we do business in TB and global health and modernize the healthcare system in high burden countries.

As the **global health landscape rapidly evolves**, so must STBP's approach to innovation. The scale and complexity of today's challenges, from the shifting donor priorities and funding environment to rapidly evolving and rising healthcare needs, demand a more comprehensive and synergistic mindset and approach.

To remain at the forefront of transformative change, **STBP must change how it engages innovators, partners, and country programs**—not just as a funder or convenor, but as an active catalyst driving the **real-world introduction, adoption, and scale-up** of innovations that deliver measurable impact.

The innovation session aims to explore how STBP can strategically evolve its innovation work—bridging ideas to implementation, connecting the global innovation ecosystem to country programs, and ensuring that every innovation reaches the people and communities who need it most.

2. Background & Context

Ending TB is not only a moral and life-saving imperative, it is also **one of the smartest public health investments** the world can make. For example, every dollar invested in ending TB yields substantial social and economic returns, improving lives, strengthening health systems, and unlocking productivity in some of the fastest-growing economies in the world¹.

While TB remains the **world's deadliest infectious disease**, TB is also **fully preventable, treatable, and curable**. No one should die from TB in the 21st century. Beyond its health burden, however, TB represents a powerful **economic and innovation opportunity**, one that can drive financial growth, build resilient health systems, and serve as a **proven pathfinder for addressing other airborne infectious diseases**. The fight against TB thus directly advances **pandemic prevention, preparedness, and response (PPPR)** goals, offering a scalable model for integrated global health security.

Notably, **19 of the 50 fastest-growing economies** are also **high burden countries**². This underscores both the challenge and the opportunity: investing in TB innovation is not only about saving lives, but also about **fueling sustainable economic growth and resilience** in the very settings where it matters most.

Through its [TB Innovation Sandbox](#) and [InnoScan](#) platform, STBP has already begun mapping and mobilizing this innovation landscape. Early analyses have identified **more than 300 product innovations**, either directly developed for TB or adaptable to TB applications, that are available or emerging in the global market. These include groundbreaking tools and technologies from countries leading in innovation, including but not limited to: 100+ from **India**; 89 from the **US**; 42 from the Republic of **Korea**; 19 from the **UK**; and 19 from **Viet Nam**.

This vibrant pipeline illustrates that the innovation ecosystem for TB is both **dynamic and geographically diverse**, yet still **fragmented and under-leveraged**. Harnessing this momentum is a critical step toward accelerating the introduction, scale-up, and access to innovations that can transform the trajectory of the TB response.

¹ Source: Pretorius, Carel et al. 2023. "One Million Lives Saved Per Year: A Cost–Benefit Analysis of the Global Plan to End Tuberculosis, 2023–2030 and Beyond." *Journal of Benefit-Cost Analysis* 14(S1): 337–54. doi: 10.1017/bca.2023.13.

² https://www.imf.org/external/datamapper/NGDP_RPCH@WEO/OEMDC/ADVEC/WEOWORLD

3. Objectives

- **Review and reflect on STBP's current innovation portfolio and progress**, highlighting key achievements and impact milestones since the 38th Board Meeting, including **advances made through TB REACH, iNTP, RTC**, and other flagship initiatives
- **Reaffirm STBP's distinctive value proposition as a global catalyst** for the introduction and scale-up of TB innovations across a complex and evolving value chain, **from product development to policy adoption and country-level implementation**
- Shape the **next phase of STBP's innovation strategy** by gathering reflections and strategic inputs on future directions, potential partnerships, and opportunities to attract **new donors and investments for upcoming innovation projects**

4. Session Flow & Time Allocation

- Part 1 (4:00-4:20 PM): **What We Have Achieved** - Presentation
- Part 2 (4:20-5:00 PM): **What Makes Us Unique** - Panel Discussion
- Part 3 (5:00-5:30 PM): **Where We Are Headed** - Presentation
- Part 4 (5:30-6:00 PM): **Board Discussion / Decision Points**

5. Speakers & Roles

Presenters:

- Dr. Jacob Creswell, Head, Innovations & Grants, Stop TB Partnership
- Ms. Jacqueline Huh, Head, External Affairs & Strategic Initiatives, Stop TB Partnership

Panelists:

- Donors / funders:
 - Ms Carrie Lehmeier, Deputy Director, Infectious Diseases and Pandemic Preparedness, Global Affairs Canada
 - Ms Hyung Won (Hannah) Lee, Deputy Country Director, Korea International Cooperation Agency (KOICA), Philippines
- Country policymaker and implementer:
 - Dr Turyahabwe Stavia, Commissioner, Communicable Disease Prevention & Control, Ministry of Health, Uganda
 - Mr Luan Vo, President, Friends for International TB Relief, Viet Nam
- Innovators:
 - Start-ups
 - Mr Michael Carnie Director of Global and Government Sales, MinXray, US
 - Dr Max Rath, Chief Medical Officer, AI Diagnostics, South Africa
 - Emerging companies
 - Mr Shiva Sriram, President - Business Development, Molbio, India
 - Multinationals

- Mr Takuma Otsuka, Head of Global Marketing and Global Health, Fujifilm, Japan

- **Board:**
 - Reviews and endorses with adjustments if needed

6. Expected Outcomes

- Robust and sustained replenishment for TB REACH, ensuring the continued ability of STBP to identify, fund, and scale breakthrough innovations that drive measurable impact in TB prevention, diagnosis, and care across high burden countries
- Scoping and initial design of an integrated, blended-finance innovation platform — a sustainable accelerator / venture mechanism that will aim to mobilize public and private capital to support the concrete, practical, and rapid roll-out of innovations across the value chain for TB, other airborne infectious diseases, and PPPR priorities
- Leveraging STBP's deep and comprehensive experience and its extensive network of country stakeholders and partners built from TB REACH, iNTP, RTC, Country and Community Support for Impact (CCS4i), and Global Drug Facility (GDF) activities to pursue additional funding opportunities to support the adoption of new innovations and approaches

7. Supporting Documents

- **TB REACH**
 - Concept note for proposals to support early Implementation of near point of care testing
- **iNTP**
 - Results reports on use of ultra-portable X-ray and CAD and Truenat
- **RTC**
 - RTC's information deck
 - RTC's country case studies from Uganda and Viet Nam
 - Accelerator / venture platform concept note and deck